Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 68, n° 3
pages 412-419 (mars 2013)
Doi : 10.1016/j.jaad.2012.07.027
accepted : 25 July 2012
Original Articles

Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States
 

Irene Cosmatos, MS a, Amy Matcho, BA a, Rachel Weinstein, PhD a, , Michael O. Montgomery, MD b, Paul Stang, PhD a
a Janssen Research and Development LLC, Titusville, New Jersey 
b Janssen Services LLC, Horsham, Pennsylvania 

Reprint requests: Rachel Weinstein, PhD, Janssen Research and Development LLC, 1125 Trenton-Harbourton Rd, PO Box 200, Titusville, NJ 08560.
Abstract
Background

Recent prevalence estimates for hidradenitis suppurativa (HS), a chronic inflammatory skin condition, are limited by timeliness, population size, and generalizability.

Objective

We sought to develop prevalence estimates for HS in the United States using large health care claims databases.

Methods

A retrospective analysis used PharMetrics Integrated Database to gather health care claims information for HS among patients with 12 or more months of continuous enrollment in a commercial health care plan throughout 2007. Included patients had: 1 or more diagnoses with International Classification of Diseases, Ninth Revision, Clinical Modification code 705.83 for HS during 2007 without a Current Procedural Terminology code for HS; 1 or more Current Procedural Terminology codes of 11450, 11451, 11462, 11463, 11470, or 11471 during 2007 without International Classification of Diseases, Ninth Revision, Clinical Modification code 705.83; or both. Age- and gender-specific prevalence projections were calculated.

Results

Among included patients (n = 7927), mean age (SD) was 38.2 (14.73) years, and 5834 (74%) were women. Most patients (n = 5205; 66%) were aged 30 to 64 years. The overall prevalence estimate was 0.053% (95% confidence interval 0.051-0.054). When adjusted for gender and age, prevalence rates were 0.052% and 0.051%, respectively. The most common procedures for HS were excision of skin and subcutaneous tissue axillary/inguinal simple or intermediate repair.

Limitations

Limitations were a health insured–only population; 12-month enrollment period for 2007; HS-specific procedural codes; and possible HS misclassifications.

Conclusion

We found a low rate of clinically detected HS (0.053%; approximately 146,000-162,000 patients in the United States in 2007), with affected persons almost 3 times as likely to be female and the highest prevalence in those aged 18 to 44 years.

The full text of this article is available in PDF format.

Key words : acne inversa, apocrine, epidemiology, hidradenitis suppurativa, prevalence

Abbreviations used : CPT , HS, ICD-9-CM



 Ms Cosmatos is currently affiliated with IMS Health Inc, Parsippany, NJ.
 Supported by Janssen Services LLC.
 Disclosure: Dr Montgomery was an employee of Janssen Services LLC, at the time of this research, and Dr Stang, Ms Cosmatos, Ms Matcho, and Dr Weinstein are or were employees of Janssen Research and Development LLC.
 Conflicts of interest: None declared.



© 2012  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline